Compare Adaptive Biotechnologies Corp (ADPT) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Corsair Gaming Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Corsair Gaming Inc trades at $8.96 (market cap $968.35M). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.4× Corsair Gaming Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CRSR | |
|---|---|---|
Market Cap | $3.33B | $968.35M |
Sector | Health | Technology |
52-Week High | $22.37 | $12.14 |
52-Week Low | $10.24 | $4.58 |
Enterprise Value | $3.19B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Corsair Gaming (CRSR) trades at $8.89, down slightly by 0.11% on the day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly results with Q1 2026 beating expectations but faces profitability challenges with a net margin of just 0.49%. Recent developments include new AI product launches and strategic partnerships, driving positive media coverage and investor optimism about future growth prospects.
The outlook remains cautiously optimistic with analyst consensus pointing to modest upside potential to the $9.00 price target. Key opportunities include expansion into AI hardware and gaming partnerships, while risks center on thin profit margins, competitive pressures, and inconsistent earnings performance. The stock offers speculative growth potential but requires careful monitoring of execution on new initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
